my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
10-05-2012: 4-Antibody AG and Evotec AG announced the signing of a strategic collaboration agreement under which Evotec will offer a fully integrated antibody discovery and development service. Evotec’s novel and unique high throughput and high content screening approach coupled with 4-Antibody’s high throughput antibody selection approach will now allow screening of large and diverse antibody populations for desired functionality and activity at a much earlier stage of selection. This unique combined approach is expected to substantially reduce attrition rates at later development stages and is also expected to be particularly beneficial in aiding earlier distinction and selection between antagonist and agonist antibodies.
Evotec’s fully integrated drug discovery and development infrastructure has been adapted to facilitate screening of human antibody populations in combination with high throughput/high content screening coupled to specific biological assays. The new collaboration integrates the output from 4-Antibody’s proprietary high throughput in vitro Retrocyte Display® technology for rapid discovery of fully human antibodies into Evotec’s high throughput cell-based assay platform.
The Retrocyte Display® technology (Retroviral B lymphocyte Display) is a high throughput cellular antibody expression platform which allows expression and screening of full-length immunoglobulin antibody libraries in mammalian B-lineage cells for the identification of antigen-specific fully human monoclonal antibodies. B-lineage cells are designed by nature for optimal antibody display and are capable of generating ‘better-behaved’, fully human antibodies.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
4-Antibody AG and Evotec AG Form Strategic Collaboration
4-Antibody AG and Evotec AG announced the signing of a strategic collaboration agreement under which Evotec will offer a fully integrated antibody discovery and development service. Evotec’s novel and unique high throughput and high content screening approach coupled with 4-Antibody’s high ... more
4-Antibody AG Meets Next Milestone in Boehringer Ingelheim Collaboration
4-Antibody AG announced the successful completion of a second milestone in its ongoing collaboration with Boehringer Ingelheim. This second milestone triggered an undisclosed fee payment. 4-Antibody’s R&D collaboration with Boehringer Ingelheim commenced in early 2010 and is a long-term co ... more
4-Antibody AG announced the signing of a multi-target research alliance with the Ludwig Institute for Cancer Research (LICR). Under the terms of the deal, the focus of the research and clinical development alliance will be on a series of molecular targets which are important in the suppress ... more
4-Antibody is a biopharmaceutical company with a powerful fully-human antibody drug-discovery technology platform. The Company is making this technology available to pharmaceutical partners and is also using it to generate a proprietary pipeline of antibody therapeutic drugs. 4-Antibody is ... more
Belfer Institute and Evotec establish collaboration in oncology
The Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Institute and Evotec AG (EVT) announced a research collaboration aimed at discovering and commercialising novel cancer treatments based on epigenetic drug mechanisms. The goal of the collaboration is to validate emerging ... more
Evotec expands compound management capability to East Coast of the United States
Evotec AG announced that Evotec (US) Inc. has executed a multi-year lease on a facility specifically designed to expand the offering of its Compound Management Services on the East Coast of the United States. Scott Snyder, Executive Vice President Compound Management of Evotec, commented: ' ... more
Evotec achieves milestone in drug discovery collaboration with Ono
Evotec AG announced that a compound identified and optimised in a research collaboration with Ono Pharmaceutical Co., Ltd. has been nominated to enter pre-clinical development, leading to the payment of an agreed milestone. This collaboration project was initiated in March 2008. Evotec co ... more
Evotec is a leading drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches. The Company operates worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
